Clinical trial
Angiotensin II Antagonism of TGF-Beta 1
NCT00320970 · Providence Health & Services, Other · Completed
Key facts
| NCT number | NCT00320970 |
|---|---|
| Title | Angiotensin II Antagonism of TGF-Beta 1 |
| Official title | Angiotensin II Antagonism of TGF-Beta 1: A Candesartan Dose - TGF-Beta 1 Response Relationship Study |
| Lead sponsor | Providence Health & Services, Other |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Diabetic Nephropathy, Hypertension |
| Intervention type | Drug |
| Interventions | Candesartan |
| Enrollment | 36 |
| Start date | Aug 1, 2002 |
| Completion | Sep 1, 2004 |
| First posted | May 3, 2006 |
| Last update posted | Aug 2, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: